Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Provention Bio Inc.
Headquarters: Oldwick, NJ, United States of America
Website: N/A
Year Founded: 2016
Status: Acquired
BioCentury | Apr 18, 2024
Management Tracks
Protego names Warner CEO
Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
BioCentury | Jan 4, 2024
Deals
Parsing premiums: 2023’s biopharma M&A deals
2023’s highest-premium takeouts and its top-value deal all came early, but 4Q was notable for its pace of $1B+ deals
BioCentury | Oct 11, 2023
Data Byte
Where Mirati’s premium falls among M&A deals this year
Mature assets have been a theme among this year’s $1B+ takeouts, but Mirati fetched one of the lowest premiums despite its marketed product
BioCentury | Sep 20, 2023
Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
BioCentury | Aug 23, 2023
Management Tracks
Mirati CFO Stelzer to depart
Plus: Peterson joins Exelixis, Eckhardt expands role at Bayer and updates from Alpine, Neuron23, Ajax
BioCentury | Jun 20, 2023
Deals
Despite IRA, Lilly’s Ricks finds path to value in Dice’s small molecules
$2.4B deal gives Lilly autoimmune programs that complement Taltz, and a platform to make more oral therapies
BioCentury | May 23, 2023
Deals
Sizing up VectivBio’s takeout premium among '23 M&A deals
Many companies with late-stage assets have commanded triple-digit premiums
BioCentury | Apr 11, 2023
Finance
April 11 Quick Takes: VintaBio debuts with $64M to tackle viral vector bottleneck
Plus: Moderna forecasts up to $15B in 2027 sales of respiratory franchise and updates from HI-Bio, Chinook, Impact-Junshi and more
BioCentury | Apr 5, 2023
Data Byte
The market cap performance of the 2018 class of U.S. IPOs
At year-end, twice as many of the companies had lost value since their IPOs than gained value
BioCentury | Mar 18, 2023
Data Byte
Friday fizzle for biotech rally
But biotech indexes stay in the black on the week
Items per page:
1 - 10 of 61